| beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing. | |
| | |
MedLine Citation:
|
PMID: 20826250 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Quality improvement programs have shown increased use of beta-blockers post-myocardial infarction (MI), but there are no data on whether appropriate doses are administered. METHODS: In a prospective registry that enrolled consecutive patients with MI, we evaluated beta-blocker dosing at discharge after MI and 3 weeks later and assessed clinical predictors for treatment with very low doses. We studied 1,971 patients (70.8% male) with a mean age of 63.9 +/- 13.7 years, of whom 48.2% had an ST-elevation MI. RESULTS: beta-Blocker utilization rates following MI were 93.2% at discharge: 20.1% received <25% of target dose, 36.5% received 25% of target dose, 26.4% received 26% to 50% of target dose, and 17.0% received >50% of target dose. Between discharge and 3 weeks, 76.4% had no change in beta-blocker dose, with 11.9% and 11.6% having their dose reduced and increased, respectively. Absence of hypertension, acute percutaneous coronary intervention, older age, and no angiotensin-converting enzyme inhibitor therapy were consistent predictors of treatment with very low beta-blocker doses. CONCLUSIONS: Underdosing of beta-blockers is highly prevalent among patients post-MI. This represents an important opportunity in quality improvement for the care of patients who have suffered an MI. |
| | |
Authors:
|
Jeffrey J Goldberger; Robert O Bonow; Michael Cuffe; Alan Dyer; Yves Rosenberg; Robert O'Rourke; Prediman K Shah; Sidney C Smith; |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: American heart journal Volume: 160 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-09 Completed Date: 2010-11-02 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 435-442.e1 Citation Subset: AIM; IM |
Copyright Information:
|
2010 Mosby, Inc. All rights reserved. |
Affiliation:
|
Northwestern University, Chicago, IL 60611, USA. j-goldberger@northwestern.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
administration & dosage* Adult Aged Aged, 80 and over Drug Utilization Evidence-Based Medicine Female Humans Male Middle Aged Myocardial Infarction / drug therapy* Physician's Practice Patterns Quality Assurance, Health Care |
| Grant Support | |
ID/Acronym/Agency:
|
U01 HL080416-02/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists |
| Investigator | |
Investigator/Affiliation:
|
P Desai / ; M Betzen / ; J Whitehill / ; L Janak / ; M Lytle / ; M Samendinger / ; E Johnson / ; C Allbritton / ; T Bacon-Howard / ; J Sparks / ; G Nair / ; T Strickland / ; D Lustgarten / ; B Alemy / ; S Forsell / ; L Chadwick / ; M Rowen / ; D Dan / ; K Picardi / ; C Schuger / ; J Dzidowski / ; L Louzon / ; J Messenger / ; B Easley / ; J Morrison / ; F Kusumoto / ; B Little / ; D Mehta / ; E Pe / ; A Simon / ; D Fintel / ; E Karpf / ; D Bello / ; S Harrison / ; S Sawyer / ; I Viera-Fleetwood / ; J Simonson / ; S Barnes / ; J LeTexier / ; M Romanelli / ; L Froehlich / ; S Teller / ; E Herzog / ; R Knox / ; W Warnica / ; D Eichman / ; D Scarcelli / ; B Smith / ; J Mounsey / ; C Blyth / ; C Schuler / ; R Germany / ; J Hubbart / ; M Panday / ; S Harris / ; A Warner / ; J Johnson / ; R Bonow / ; M Cuffe / ; A Dyer / ; J Goldberger / ; R O'Rourke / ; P Shah / ; Y Rosenberg / ; S Smith / ; R Byington / ; M Domanski / ; Z Feng / ; S Goldberg / ; S Goldstein / ; J Kirkpatrick / ; C Love / ; S Singh / ; J Goldberger / ; C Ball / ; J Cahill / ; A Schaechter / ; D Lizcano / ; T Plant / ; A Rosenfeld / ; J Simon / ; A Kadish / ; K Ma / ; H Subacius / |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear ...
Next Document: A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the ...